Drug Development [Letter of Intent]
The Drug Development RFP supports investigational new drug (IND)-enabling studies (or the international equivalent) and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.

This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.

Award Amount:
Up to $5,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Payment structure will be negotiated and based on milestone achievements and recruitment.

Neuroimaging and CSF Biomarker Program [Letter of Intent]
The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

Specifically, this RFP focuses on:
- Developing novel PET ligands for clinical trials
- Supporting novel CSF biomarkers
- Validating innovative MRI approaches in larger cohorts
- Developing novel measures of functional activity such as EEG

Award Amount:
Up to $600,000 based on stage and scope of research.

Prevention Pipeline [Letter of Intent]
The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

The Prevention RFP supports:
- Studies of Cognitive Decline and Risk Reduction
- Comparative Effectiveness Research
- Studies Leveraging the Consortium of Cohorts for Alzheimer's Prevention Action (CAPA)

Award Amount:
- Up to $5,000,000 for clinical trials based on stage and scope of research
- For studies requiring additional support, co-funding from other funding agencies or investors is encouraged
- Payment structure will be negotiated and based on milestone achievements and recruitment

Accelerating Drug Discovery for FTD [Letter of Intent]
There are currently no FDA approved disease-modifying treatments available for frontotemporal dementia (FTD), and symptomatic treatments only provide limited benefit for patients. Recent scientific advances have provided an increased understanding of pathogenic mechanisms underlying FTD and are driving the development of potential disease-modifying therapies. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate this progress by supporting innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy etc.) drug development programs for FTD through this request for proposals (RFP).

$300,000-$350,000 based on stage and scope of research. Slightly higher budgets can be considered. Please contact us for review and approval.